C12N 2840/007
Cell or tissue specific
Official title: cell or tissue specific
C12N2840/007 (Cell or tissue specific) appears on 73 US grants and 148 published applications in this corpus.
Search patents in C12N- Granted patents
- 73
- Published applications
- 148
- Assignees
- 90
- Inventors
- 269
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 1 | 1 |
| 2006 | 1 | 0 |
| 2007 | 0 | 2 |
| 2008 | 0 | 1 |
| 2009 | 1 | 3 |
| 2010 | 0 | 1 |
| 2011 | 0 | 1 |
| 2012 | 0 | 1 |
| 2013 | 0 | 4 |
| 2014 | 2 | 6 |
| 2015 | 3 | 4 |
| 2016 | 3 | 2 |
| 2017 | 4 | 18 |
| 2018 | 2 | 8 |
| 2019 | 12 | 20 |
| 2020 | 5 | 16 |
| 2021 | 9 | 13 |
| 2022 | 7 | 9 |
| 2023 | 6 | 11 |
| 2024 | 6 | 8 |
| 2025 | 4 | 10 |
| 2026 | 7 | 8 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Self-complementary adeno-associated virus vector and its use in treatment of muscular dystrophy15 Sep 2026US 12,735,723 B2Research Institute At Nationwide Children's Hospital
- Aptamer and ribozyme equilibrium shifting (ARES) RNA circuits and uses thereof7 Jul 2026US 12,674,171 B2Trustees of Boston University
- Regulatable adeno-associated virus (AAV) vector2 Jun 2026US 12,642,869 B2Georg-August-UniversitäT GöTtingen Stiftung öFfentlichen Rechts, UniversitäTsmedizin
- Prostate targeting adeno-associated virus serotype vectors26 May 2026US 12,636,382 B2University of Massachusetts
- GM3 synthase vectors and uses thereof17 Feb 2026US 12,553,036 B2The Clinic for Special Children, Inc.
- Expression constructs, fusogenic lipid-based nanoparticles and methods of use thereof8 Oct 2026US 2026/0308635 A1Oisin Biotechnologies, Inc.
- Gm3 synthase vectors and uses thereof23 Jul 2026US 2026/0209721 A1The Clinic for Special Children, Inc.
- Oncoselective therapy14 May 2026US 2026/0132180 A1Kernal Biologics, Inc.
- Tissue specific synthetic promoters and circuits and use thereof26 Mar 2026US 2026/0085102 A1Yissum Research Development Company of the Hebrew University of Jerusalem
- Compositions and methods for selective gene regulation19 Mar 2026US 2026/0078404 A1Encoded Therapeutics, Inc.
Most cited
By later US patents
- Isolation of novel AAV'S and uses thereof107US 9,217,155 B2University of Massachusetts · 2015
- CNS targeting AAV vectors and methods of use thereof91US 9,102,949 B2University of Massachusetts · 2015
- Isolation of novel AAV's and uses thereof63US 9,596,835 B2University of Massachusetts · 2017
- CNS targeting AAV vectors and methods of use thereof57US 9,701,984 B2University of Massachusetts · 2017
- Isolation of novel AAV's and uses thereof28US 10,300,146 B2University of Massachusetts · 2019